Jauch KW - Search Results

1

Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies.

Kleespies A, Bruns CJ, Jauch KW. Kleespies A, et al. Among authors: jauch kw. Onkologie. 2005 May;28(5):281-8. doi: 10.1159/000085198. Epub 2005 Apr 29. Onkologie. 2005. PMID: 15867486 Free article.

2

Vascular endothelial growth factor in colorectal cancer.

Guba M, Seeliger H, Kleespies A, Jauch KW, Bruns C. Guba M, et al. Among authors: jauch kw. Int J Colorectal Dis. 2004 Nov;19(6):510-7. doi: 10.1007/s00384-003-0576-y. Epub 2004 Mar 4. Int J Colorectal Dis. 2004. PMID: 14999511 Review.

3

Vascular endothelial growth factor in esophageal cancer.

Kleespies A, Guba M, Jauch KW, Bruns CJ. Kleespies A, et al. Among authors: jauch kw. J Surg Oncol. 2004 Aug 1;87(2):95-104. doi: 10.1002/jso.20070. J Surg Oncol. 2004. PMID: 15282704 Review.

4

Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF.

Guba M, Yezhelyev M, Eichhorn ME, Schmid G, Ischenko I, Papyan A, Graeb C, Seeliger H, Geissler EK, Jauch KW, Bruns CJ. Guba M, et al. Among authors: jauch kw. Blood. 2005 Jun 1;105(11):4463-9. doi: 10.1182/blood-2004-09-3540. Epub 2005 Jan 25. Blood. 2005. PMID: 15671443 Free article.

5

miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression.

Wang Y, Zhao Y, Herbst A, Kalinski T, Qin J, Wang X, Jiang Z, Benedix F, Franke S, Wartman T, Camaj P, Halangk W, Kolligs FT, Jauch KW, Nelson PJ, Bruns CJ. Wang Y, et al. Among authors: jauch kw. Ann Surg. 2016 Nov;264(5):804-814. doi: 10.1097/SLA.0000000000001928. Ann Surg. 2016. PMID: 27501171

6

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Guba M, et al. Among authors: jauch kw. Nat Med. 2002 Feb;8(2):128-35. doi: 10.1038/nm0202-128. Nat Med. 2002. PMID: 11821896

7

Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.

Kleespies A, Köhl G, Friedrich M, Ryan AJ, Barge A, Jauch KW, Bruns CJ. Kleespies A, et al. Among authors: jauch kw. Neoplasia. 2005 Oct;7(10):957-66. doi: 10.1593/neo.05304. Neoplasia. 2005. PMID: 16242078 Free PMC article.

8

Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer?

Kleespies A, Jauch KW, Bruns CJ. Kleespies A, et al. Among authors: jauch kw. Drug Resist Updat. 2006 Feb-Apr;9(1-2):1-18. doi: 10.1016/j.drup.2006.02.002. Epub 2006 Apr 18. Drug Resist Updat. 2006. PMID: 16621676 Review.

9

The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.

Schmid G, Guba M, Ischenko I, Papyan A, Joka M, Schrepfer S, Bruns CJ, Jauch KW, Heeschen C, Graeb C. Schmid G, et al. Among authors: jauch kw. J Cell Biochem. 2007 May 1;101(1):259-70. doi: 10.1002/jcb.21181. J Cell Biochem. 2007. PMID: 17203465

10

Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.

Conrad C, Ischenko I, Köhl G, Wiegand U, Guba M, Yezhelyev M, Ryan AJ, Barge A, Geissler EK, Wedge SR, Jauch KW, Bruns CJ. Conrad C, et al. Among authors: jauch kw. Anticancer Drugs. 2007 Jun;18(5):569-79. doi: 10.1097/CAD.0b013e3280147d13. Anticancer Drugs. 2007. PMID: 17414626

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

606 results

Search Page

Filters